Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $49.70
    -0.95 (-1.88%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Travere Therapeutics Inc (TVTX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Travere Therapeutics (TVTX) to earn $0.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $765.32M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.

    RatingAnalystsShare
    Strong Buy213.3%
    Buy1280.0%
    Hold16.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 922.6% and revenue estimates rise 49.0%.

    Fiscal year ending Dec 31, 2026
    $0.53
    EPS consensus, revenue $765.32M
    Fiscal year ending Dec 31, 2027
    $5.42
    EPS consensus, revenue $1.14B

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.53$0.33 to $0.817$765.32M$739.68M to $782.20M14
    Dec 31, 2027$5.42$4.16 to $6.638$1.14B$882.67M to $1.38B14

    Quarterly Estimates

    The EPS consensus rises from $0.48 for the quarter ending Dec 31, 2026 to $1.05 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.48$0.09 to $0.9916$243.08M$206.78M to $279.30M16
    Mar 31, 2027$1.05$0.80 to $1.275$254.72M$231.81M to $282.20M8

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202602
    Fiscal year ending Dec 31, 202713
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 69.9% from $1.76.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.53$1.67$1.74$1.74$1.76-69.7%
    Fiscal year ending Dec 31, 2027$5.42$5.70$5.67$5.67$5.49-1.3%
    Quarter ending Mar 31, 2027$1.05$1.05$1.01$1.01$0.96+9.6%

    Frequently Asked Questions About TVTX

    What is the TVTX stock forecast?

    Consensus analyst estimates put Travere Therapeutics's EPS at $0.53 for the fiscal year ending Dec 31, 2026, on revenue of $765.32M. The consensus rating from 15 analysts is Buy.

    How do analysts rate TVTX stock?

    Of 15 analysts covering Travere Therapeutics, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TVTX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.53, with estimates from $0.33 to $0.81 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.42, with estimates from $4.16 to $6.63 from 8 analysts.

    What revenue do analysts expect from Travere Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $765.32M, with estimates from $739.68M to $782.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.14B, with estimates from $882.67M to $1.38B.

    How many analysts cover TVTX?

    15 analysts rate Travere Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.